Skip to main content

Advertisement

SpringerLink
Log in

Abiraterone Acetate

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Cougar Biotechnology Inc. Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data at ASCO Annual Meeting. http://www.cougarbiotechnology.com, 01 Jun 2009 Media Release

    Google Scholar 

  2. Johnson & Johnson. Johnson & Johnson Completes Acquisition of Cougar Biotechnology. http://www.jnj.com, 10 Jul 2009 Media Release

    Google Scholar 

  3. Ortho Biotech Oncology Research & Development. Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer. http://www.centocororthobiotech.com, 11 Oct 2010 Media Release

    Google Scholar 

  4. BTG, Cougar Biotechnology. BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology. http://www.btgplc.com, 20 Apr 2004 Media Release

    Google Scholar 

  5. Cougar Biotechnology Inc. Cougar Biotechnology Announces Initiation of Phase III Trial of CB7630 (Abiraterone Acetate). http://www.cougarbiotechnology.com, 30 Apr 2008 Media Release

    Google Scholar 

  6. BTG PLC. BTG plc: Abiraterone Acetate Meets Pre-Determined Criteria in Metastatic Prostate Cancer Study. http://www.btgplc.com, 10 Sep 2010 Media Release

    Google Scholar 

  7. Ortho Biotech Oncology Research & Development. Study of Investigational Agent Abiraterone Acetate for Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria. http://www.jnjpharmarnd.com, 09 Sep 2010 Media Release

    Google Scholar 

  8. Cougar Biotechnology Inc. Cougar Biotechnology Initiates Phase III Trial of CB7630 (Abiraterone Acetate) in Chemotherapy-Naïve Castration-Resistant Prostate Cancer Patients. http://www.cougarbiotechnology.com, 30 Apr 2009 Media Release

    Google Scholar 

  9. Cougar Biotechnology Inc. Cougar Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III Trial of CB7630 (Abiraterone Acetate) in Chemotherapy Naïve Castration Resistant Prostate Cancer Patients. http://www.cougarbiotechnology.com, 11 Feb 2009 Media Release

    Google Scholar 

  10. Cougar Biotechnology Inc. Cougar Biotechnology Announces Presentation of Positive CB7630 Phase I Clinical Data at ASCO 2008 Genitourinary Cancers Symposium. http://www.cougarbiotechnology.com, 16 Feb 2008 Media Release

    Google Scholar 

  11. Cougar Biotechnology Inc. Cougar Biotechnology Announces Initiation of Phase I Trial for CB7630 (Abiraterone Acetate). http://www.cougarbiotechnology.com, 11 Jul 2006 Media Release

    Google Scholar 

  12. Cougar Biotechnology Inc. Positive Phase II Data on Cougar Biotechnology’s CB7630 Presented at Prostate Cancer Foundation Scientific Retreat. http://www.cougarbiotechnology.com, 18 Oct 2008 Media Release

    Google Scholar 

  13. Cougar Biotechnology Inc. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session. http://www.cougarbiotechnology.com, 18 Apr 2007 Media Release

    Google Scholar 

  14. Cougar Biotechnology Inc. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting. http://www.cougarbiotechnology.com, 04 Jun 2007 Media Release

    Google Scholar 

  15. Cougar Biotechnology Inc. Cougar Biotechnology Initiates Phase II Trial of CB7630 (Abiraterone Acetate). http://www.cougarbiotechnology.com, 15 Dec 2006 Media Release

    Google Scholar 

  16. Phase 1 Study of JNJ-212082 (Abiraterone Acetate) in Patients With Castration-Resistant Prostate Cancer. Clinical Trial Profile

  17. BTG PLC. BTG plc: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer. http://www.btgplc.com, 22 Jul 2008 Media Release

    Google Scholar 

  18. Cougar Biotechnology Inc. Cougar Biotechnology Reports 2008 Fourth Quarter and Year-End Financial Results. http://www.cougarbiotechnology.com, 17 Mar 2009 Media Release

    Google Scholar 

  19. Cougar Biotechnology Inc. Cougar Biotechnology Announces Initiation of Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breast Cancer Patients. http://www.cougarbiotechnology.com, 21 Nov 2008 Media Release

    Google Scholar 

  20. Carden CP, Raynaud FI, Jones RL, et al. Crossover pharmacokinetics study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer. 44th Annual Meeting of the American Society of Clinical Oncology: (plus poster) abstr. 5168, 30 May 2008. Available from URL: http://www.asco.org [English]

    Google Scholar 

  21. Cougar Biotechnology Inc. Cougar Biotechnology Presents Positive CB7630 Phase I data at the AACR Innovations in Prostate Cancer Research Conference. http://www.cougarbiotechnology.com, 09 Dec 2006 Media Release

    Google Scholar 

  22. Cougar Biotechnology Inc. Cougar Biotechnology Announces Positive CB7630 Phase I data Presented at the National Cancer Research Institute Conference. http://www.cougarbiotechnology.com, 09 Oct 2006 Media Release

    Google Scholar 

  23. Barrie SE, Potter GA, Goddard PM, et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994; 50: 267–73

    Article  PubMed  CAS  Google Scholar 

  24. Cougar Biotechnology Inc. Cougar Biotechnology Announces Presentation of Positive CB7630 (Abiraterone Acetate) Phase II Data at ASCO 2009 Genitourinary Cancers Symposium. http://www.cougarbiotechnology.com, 28 Feb 2009 Media Release

    Google Scholar 

  25. Cougar Biotechnology Inc. Cougar Biotechnology Presents CB7630 Phase I Clinical Data at the 2005 Prostate Cancer Symposium. http://www.cougarbiotechnology.com, 21 Feb 2005 Media Release

    Google Scholar 

  26. Cougar Biotechnology Inc. Cougar Biotechnology Presents CB7630 Phase I Data at Prostate Cancer Foundation Scientific Retreat. http://www.cougarbiotechnology.com, 25 Oct 2004 Media Release

    Google Scholar 

  27. Cougar Biotechnology Inc. Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase I and Phase II Data at ASCO 2008 Annual Meeting. http://www.cougarbiotechnology.com, 03 Jun 2008 Media Release

    Google Scholar 

  28. Danila DC, Rathkopf DE, Morris MJ, et al. Abiraterone acetate and prednisone in patients with progressive metastatic castration resistant prostate cancer after failure of docetaxel-based chemotherapy. 44th Annual Meeting of the American Society of Clinical Oncology: (plus oral presentation) abstr. 5019, 30 May 2008. Available from URL: http://www.asco.org [English]

    Google Scholar 

  29. Reid AHM, Attard G, Molife R, et al. Abiraterone, an oral, irreversible CYP450c17 enzyme inhibitor appears to have activity in post-docetaxel castration refractory prostate cancer patients. 98th Annual Meeting of the American Association for Cancer Research: Clinical Research Track. (Spec. issue 3): abstr. LB-181, 14 Apr 2007. England [English]

    Google Scholar 

  30. Attard G, Reid AHM, Barrett M, et al. Inhibition of androgen synthesis results in a high response rate in castration refractory prostate cancer. 98th Annual Meeting of the American Association for Cancer Research: Clinical Research Track. (Spec. issue 3): abstr. LB-180, 14 Apr 2007. England [English]

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abiraterone Acetate. Drugs R D 10, 261–269 (2010). https://doi.org/10.2165/11587960-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11587960-000000000-00000

Keywords

Search

Navigation